<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01392768</url>
  </required_header>
  <id_info>
    <org_study_id>ACH-LPT-03(09/10)</org_study_id>
    <nct_id>NCT01392768</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Levetiracetam in Partial Seizures Control, With or Without Secondary Generalization</brief_title>
  <acronym>Mozart</acronym>
  <official_title>A Double-blind, Phase III, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Levetiracetam as Adjunctive Therapy, in Partial Seizures Control Associated With Refractory Focal Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ache Laboratorios Farmaceuticos S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ache Laboratorios Farmaceuticos S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether levetiracetam as adjunctive therapy is&#xD;
      effective in the treatment of partial seizures, with or without secondary generalization,&#xD;
      associated with refractory focal epilepsy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Partial onset seizure frequency per week.</measure>
    <time_frame>From baseline to week 24</time_frame>
    <description>Collection of seizure count throughout the whole study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety descriptive about occurence of adverse events, evaluation of results of clinical/physical examination and ECG and laboratory tests results.</measure>
    <time_frame>From baseline to week 30</time_frame>
    <description>Collection of safety data throughout the whole study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of response between the groups of treatment. (Responders defined as number of patients with at least 50% reduction in the number of weekly partial seizures)</measure>
    <time_frame>From baseline to week 24</time_frame>
    <description>Comparative between baseline and treatment periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage reduction from baseline in partial seizure frequency of days a week.</measure>
    <time_frame>From baseline to week 24</time_frame>
    <description>Comparative between baseline and treatment periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of response between the groups of treatment. (Responders defined as number of subjects with at least 50% reduction in the number of days per week with partial seizures)</measure>
    <time_frame>From baseline to week 24</time_frame>
    <description>Comparative between baseline and treatment periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion between the groups of treatment without any kind of seizures. (seizure free)</measure>
    <time_frame>12 weeks after the titration period (period with stable regimen of the drug)</time_frame>
    <description>During the evaluation period of treatment, without the titration period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Epilepsy</condition>
  <condition>Partial Seizures</condition>
  <arm_group>
    <arm_group_label>Levetiracetam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <description>Oral solution (Each mL contains 100mg of levetiracetam) or immediate-release tablets (Tablets containing 500mg or 1000mg of levetiracetam)</description>
    <arm_group_label>Levetiracetam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, properly standardized to suit the characteristics of each dosage form (oral solution and tablets) of levetiracetam</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of both sexes, aged between 04 and 65 years, remaining the feasibility of a&#xD;
             legal guardian in accordance with need, able to understand and provide written&#xD;
             informed consent and able to allow compliance at the treatment and the requirements of&#xD;
             the protocol;&#xD;
&#xD;
          -  Patient´s weight ≥ 20kg;&#xD;
&#xD;
          -  Consistent diagnosis of refractory focal epilepsy, with or without secondary&#xD;
             generalization;&#xD;
&#xD;
          -  Patient with onset of seizures for at least 02 years preceding the screening visit;&#xD;
&#xD;
          -  Presence at least 12 partial seizures during the 03 months preceding the screening&#xD;
             visit (04 seizures per month);&#xD;
&#xD;
               -  Only seizures that generate motor manifestation will be recorded in this study.&#xD;
&#xD;
          -  Absence of brain injury progressive or expansive, previously documented by CT scan,&#xD;
             MRI or other imaging test applicable (in the last 05 years;&#xD;
&#xD;
          -  Patient with electroencephalogram performed up to 02 years before this visit;&#xD;
&#xD;
          -  Subject with stable regimen (minimum of 01 month) from one to three antiepileptic&#xD;
             drugs.&#xD;
&#xD;
               -  Vagus nerve stimulation for 04 weeks prior to V1, or use of benzodiazepines for&#xD;
                  more than 07 consecutive days will be considered as concomitant epileptic drugs)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with:&#xD;
&#xD;
               -  Seizures of non epileptic origin;&#xD;
&#xD;
               -  Pseudoseizures;&#xD;
&#xD;
               -  Seizures occurring in clustered patterns (03 or more seizures in 30 minutes), in&#xD;
                  the 03 months preceding the screening visit (V1);&#xD;
&#xD;
               -  History of status epilepticus while taking antiepileptic drugs during the 03&#xD;
                  months that preceding the screening visit (V1).&#xD;
&#xD;
          -  Epileptic syndromes that occurs with cognitive deficits or secondary epilepsy evolving&#xD;
             from some brain disease;&#xD;
&#xD;
          -  History of schizophrenia or suicide attempt;&#xD;
&#xD;
          -  Patients with psychiatric ill ongoing;&#xD;
&#xD;
          -  Presence of severe mental retardation of any etiology;&#xD;
&#xD;
          -  Previous exposure to levetiracetam;&#xD;
&#xD;
          -  Women of childbearing age who had tested positive for pregnancy, or who do not use&#xD;
             acceptable contraceptive method, or do not agree to practice reliable contraception&#xD;
             during the study;&#xD;
&#xD;
          -  Woman in pregnancy or lactation period;&#xD;
&#xD;
          -  Diagnosis of renal or hepatic failure;&#xD;
&#xD;
          -  Patients with genetic syndromes;&#xD;
&#xD;
          -  Patient that is taking any prohibited medication (Item 9.3);&#xD;
&#xD;
          -  Participation in last one year of clinical protocols, unless it can be direct benefit&#xD;
             to subject;&#xD;
&#xD;
          -  Relatives of sponsor´s or study site´s employee;&#xD;
&#xD;
          -  Current evidence of clinically significant diseases: hematopoietic, gastrointestinal,&#xD;
             cardiovascular, hepatic, renal, neurological, endocrine, psychiatric, autoimmune,&#xD;
             pulmonary, or another disease that block the subject participation;&#xD;
&#xD;
          -  Any finding of clinical observation (anamnesis and physical exam) laboratory&#xD;
             abnormality (e.g., blood glucose, blood count), disease (for example, liver,&#xD;
             cardiovascular system, lung) or therapy that, in opinion of the investigator, may&#xD;
             endanger the subject or interfere with the endpoints of study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elza M Yacubian</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of São Paulo</affiliation>
  </overall_official>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>July 6, 2011</study_first_submitted>
  <study_first_submitted_qc>July 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2011</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>Partial</keyword>
  <keyword>Seizures</keyword>
  <keyword>Adjunctive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levetiracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

